biosimilar

(redirected from Biogenerics)
Also found in: Medical.

bi·o·sim·i·lar

 (bī′ō-sĭm′ə-lər)
adj.
Highly similar in function and effect to an existing biological product, especially to a biologic that has already been clinically tested and approved for use.
n.
A biological product that is biosimilar to an existing product, especially to a biologic.
References in periodicals archive ?
There is a very healthy worldwide pipeline of products in development, with over 800 biosimilars, here including about 200 biogenerics, in development and a number of already marketed biosimilars worldwide.
Generic medicines and biogenerics will be crucial to curbing the growth of rapidly expanding health costs moving forward.
Practitioners working at pharmaceutical companies and universities in the US, Europe, and Japan review basic antibody biology and sources, engineering, physiology and in vivo biology, characterization, expression, production and delivery in animals and plants, therapeutic targets, clinical use and clinical trials, and biogenerics and biosimilars.
This partnership gives Hospira access to Celltrion's large biogenerics portfolio, and is an excellent example of Hospira's commitment to organic and inorganic growth," Hospira Chief Executive Chris Begley said.
market for generic versions of biotechnology products, called biosimilars or biogenerics, at $45 million by 2015, if the federal government clears a regulatory path for such products.
The mere fact that the FTC is conducting this roundtable demonstrates the growing momentum behind ensuring that consumers have access to safe and affordable biogenerics sooner rather than later.
At the conference I was repeatedly asked for my opinion on when the United States would develop coherent rules on biogenerics or biosimilars.
This study examines the potential US market for biogenerics over the next 10 and 20 years and concludes that the savings for patients and the health care system would be very large: Our analysis found that generic versions of the top 12 categories of biologic treatments with patent protections that have expired or are due to expire in the near future could save Americans, in net present value, $67 billion to $108 billion over the first 10 years and $236 billion to $378 billion over 20 years.
The biotech drug industry has benefited in general from high prices, but the recent refusal of a number of health insurance organizations to pay for new biotech drugs and the development of biogenerics are likely to bring about a change in pricing strategy.
This act would bring in competition and institute a framework regulating the production of biogenerics to ensure they are equivalent to the original.
However, in the related space - drug chain stores and biogenerics are two new arenas which we see as next growth drivers - we have analyzed these two novel spaces as well in this report.